Mid term results of nitinol self-expanding stent (LifeStent (R)) implantation for femoropopliteal occlusion disease

Abstract

Objective To evaluate the up to mid term safety and efficacy of nitinol self-expanding stent (LifeStent (R)) implantation for femoropopliteal lesions.Methods In this study,67 patients (68 limbs) with de novo femoropopliteal lesions were treated by implanting a nitinol self-expanding stent (LifeStent,Bard Inc) from January 2012 through April 2013.Mean age was (72 ± 10) years,including critical limb ischemia in 19 limbs (27.9％),ankle brachial index (ABI) was 0.44 ±0.18 on baseline,the mean lesion length was (128 ± 73) mm.The endpoints was target lesion revascularization (TLR),patency rate,and limb salvage.Post-operative ABI,and complications.Results Post-operative ABI was (0.82 ± 0.18),significantly increased after operations (P ＜ 0.01).Mean follow-up time was (7 ± 4) months,with 7 patients lost to follow-up.Freedom from TLR,primary patency rate and secondary patency rate at 6 and 12 months were 94.4％ ±3.1％ and 83.5％ ±6.5％,90.7％ ±3.9％ and 73.3％ ±7.7％,98.1％ ± 1.8％ and 90.3％ ± 5.6％,respectively.Limb salvage rate at 12 months was 94.1％ ± 4.4％.Complications occurred in 8 limbs.There was no severe complications and inhospital mortality.Conclusions Nitinol self-expanding stent implantation for femoropopliteal lesions appears to be safe and efficient,based on its satisfactory clinical outcomes during a short-to mid-term follow up. Key words: Arterial occlusive diseases ; Stents ; Femoropopliteal